Deepcell and InGel Therapeutics partner to advance ocular cell therapies

Deepcell, a company specialising in AI-powered, label-free single cell morphology profiling and sorting, will provide its REM-I platform to integrate into InGel Therapeutics’ therapeutic development pipeline. The companies said the REM-I platform enables high-dimensional morphological insights that …